Added to YB: 2026-10-07
Pitch date: 2026-10-01
FENC [bullish]
Fennec Pharmaceuticals Inc.
-1.05%
current return
Author Info
Focused on healthcare and biotech businesses with multibagger potential or significant upside. Sign up for the newsletter.
Company Info
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Market Cap
$372.4M
Pitch Price
$10.46
Price Target
103.30 (+898%)
Dividend
N/A
EV/EBITDA
-324.25
P/E
-104.78
EV/Sales
5.59
Sector
Biotechnology
Category
growth
92% Gross Margins, 78% Growth, and a Setup Where Doubling Is the Conservative Case - $FENC
FENC: Fennec has turned PEDMARK into a profitable, high-growth specialty-pharma business: 2025 gross margin was 92%, Q2 2026 sales rose 78%, and adjusted EBITDA reached $2.8 million. At a $331 million enterprise value, the underpenetrated US pediatric label plus up to $230 million of European milestones supports a stated 2x-10x multi-year possibility, explicitly an educated guess; AYA expansion lacks a defined regulatory path and scaling may require reinvestment.
Read full article (27 min)